iX Biopharma Successfully Completes S\$6 Million Share Placement, Expanding Share Base

Key Highlights of the Announcement

• Successful Completion of Private Placement:
  iX Biopharma Ltd. has completed a significant capital raising exercise through the issuance of 75,800,000 new shares, raising gross proceeds of no less than S\$6,000,000.
• Increase in Share Capital:
  As a result of this placement, the company’s total issued shares have increased from 960,495,895 to 1,036,295,895.
• Listing and Trading of New Shares:
  The newly issued shares are expected to be listed and quoted on the Catalist board of the Singapore Exchange (SGX-ST) on or around 26 February 2026. Trading of these shares will commence at 9:00 a.m. on the same day.
• Parity with Existing Shares:
  The new shares will rank pari passu with the existing shares, meaning they have the same rights as current shareholders.

Details Investors Should Note

• Share Dilution: The placement increases the total share base by approximately 7.9%. Existing shareholders should be aware of potential dilution effects, which may impact earnings per share and individual voting power.
• Potential Share Price Impact: The inflow of new shares and the company’s strengthened cash position could be a catalyst for share price movement. The market’s reaction will depend on how well the funds are deployed and investor sentiment regarding the dilution versus the company’s growth prospects.
• Regulatory Note: The shares have not been registered under the U.S. Securities Act of 1933 or any U.S. state securities laws. As such, they are not offered or sold in the United States unless an exemption applies. This means international investors, especially U.S.-based ones, face restrictions.
• Sponsor Review: The announcement has been reviewed by UOB Kay Hian Private Limited, the company’s sponsor. However, the SGX-ST has neither examined nor approved the announcement content, and bears no responsibility for its accuracy.

What This Means for Shareholders

The successful completion of the S\$6 million placement signals investor confidence and provides iX Biopharma with additional capital to potentially fund new business initiatives, R&D, or operational expansion. However, shareholders should closely monitor how the raised funds are utilized and any subsequent communications from the company regarding capital deployment.

The expansion of the share base could influence future financial ratios and per-share metrics. It is important for current and potential investors to consider both the positive aspects of capital inflow and the potential for short-term share price volatility due to dilution.

Next Steps and Key Dates

• Listing of New Shares: 26 February 2026
• Commencement of Trading: 9:00 a.m. on 26 February 2026

Contact Information

For further details, the sponsor’s contact is Mr. Lance Tan, Senior Vice President, UOB Kay Hian Private Limited, 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920. Tel: (65) 6590 6881.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors are advised to conduct their own due diligence and consult professional advisors before making any investment decisions. Neither the reporter nor the publisher assumes any responsibility for actions taken based on the information provided above. The Singapore Exchange Securities Trading Limited (SGX-ST) assumes no responsibility for the contents of this article.

View IX BiopharmaW260718 Historical chart here